CFO Atabak Mokari sold 40,000 shares ($3.2M) at $80.02–$82.45 on 2026-06-15 via scheduled 10b5-1 plan; retains 16,130 non-derivative shares and 20,000 option holdings.
CFO Atabak Mokari executed four separate sales totaling 40,000 shares for $3,245,900.04 on 2026-06-15 under a pre-arranged 10b5-1 trading plan adopted 2025-12-12, reducing his non-derivative holdings by 71.3% from 56,130 shares to 16,130 shares. The sales occurred at prices ranging from $80.02 to $82.45 (blended average $81.15), while the stock now trades at $81.75 and has climbed 139.9% over the past 90 days and 48.3% over the past 30 days from a 52-week range of $28.66–$91.00. Corcept is trading at a P/E of 185.80 with a -$31.8M net loss in the latest quarter despite $164.9M in revenue and 12.8% annual growth. Because this sale is scheduled under a 10b5-1 plan rather than discretionary, it reflects a pre-established trading arrangement rather than a timing decision by the insider; the executive retains 20,000 shares via stock options alongside his 16,130 non-derivative shares.